Enveric Biosciences (ENVB)
NASDAQ:ENVB
Want to see ENVB full AI Analyst Report?
ENVB Stock Chart & Stats
$3.72
-$0.12(-23.95%)
At close: 4:00 PM EST
$3.72
-$0.12(-23.95%)
Day’s Range― - ―
52-Week Range$1.71 - $17.63
Previous CloseN/A
Volume362.16K
Average Volume (3M)781.31K
Market Cap
$8.14M
Enterprise Value-$3.59M
Total Cash (Recent Filing)$4.91M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-27.34
Shares Outstanding3,681,884
10 Day Avg. Volume899,153
30 Day Avg. Volume781,309
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.29
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap-0.44
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit22.85
Enterprise Value/Ebitda0.45
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-315
Revenue Forecast (FY)$10.00M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt reduces interest burden and financial distress risk for a pre-commercial biotech. Structurally, low leverage preserves flexibility to direct cash toward R&D and IND-enabling work, improving optionality for partnerships or milestone-focused financings over the next 2–6 months.
Strengthening Intellectual PropertyA reinforced patent estate (including the withdrawal of a challenge) creates a durable barrier to competition around EB-003 and related chemistry. Strong IP supports future licensing, collaborations, or acquisition discussions and materially improves long-term commercial and negotiating leverage for a small pipeline biotech.
Near-term Funded IND-enabling RunwayRaised proceeds and current cash provide runway to complete preclinical work and prepare an IND, reducing immediate financing pressure. Achieving IND-enabling milestones is a structural de-risking event that can catalyze partnerships or targeted financings rather than continuous dilutive raises.
Bears Say
No Revenue; Persistent Cash BurnThe firm remains pre-revenue with sustained negative operating and free cash flow, meaning continued reliance on external capital to fund R&D. Structurally, ongoing cash burn elevates dilution risk and limits runway absent meaningful expense cuts or milestone financing, pressuring long-term program continuity.
Small Equity Base And Limited Financial FlexibilityA small equity cushion and modest asset base constrain the company's ability to absorb further losses or secure non-dilutive financing. Structurally this weak balance-sheet profile reduces bargaining power with partners and increases the likelihood of dilutive capital raises to sustain pipeline advancement.
Corporate Vote Signals Material Dilution RiskProposals to authorize large share increases and a reverse split are governance levers often used to preserve listing and enable sizable future financings. Structurally, these actions indicate management is preparing for significant capital raises, implying elevated dilution risk for existing shareholders over the medium term.
Enveric Biosciences News
ENVB FAQ
What was Enveric Biosciences’s price range in the past 12 months?
Enveric Biosciences lowest stock price was $1.71 and its highest was $17.63 in the past 12 months.
What is Enveric Biosciences’s market cap?
Enveric Biosciences’s market cap is $8.14M.
When is Enveric Biosciences’s upcoming earnings report date?
Enveric Biosciences’s upcoming earnings report date is Aug 17, 2026 which is in 82 days.
How were Enveric Biosciences’s earnings last quarter?
Enveric Biosciences released its earnings results on May 15, 2026. The company reported -$1.082 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.082.
Is Enveric Biosciences overvalued?
According to Wall Street analysts Enveric Biosciences’s price is currently Overvalued.
Does Enveric Biosciences pay dividends?
Enveric Biosciences does not currently pay dividends.
What is Enveric Biosciences’s EPS estimate?
Enveric Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enveric Biosciences have?
Enveric Biosciences has 3,681,884 shares outstanding.
What happened to Enveric Biosciences’s price movement after its last earnings report?
Enveric Biosciences reported an EPS of -$1.082 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.747%.
Which hedge fund is a major shareholder of Enveric Biosciences?
Currently, no hedge funds are holding shares in ENVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Enveric Biosciences
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Indaptus Therapeutics
―
GT Biopharma
―
Artelo Biosciences
―
Ownership Overview
4.27% Insiders
0.22% Mutual Funds
0.46% Other Institutional Investors
94.20% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---